[Congressional Bills 117th Congress]
[From the U.S. Government Publishing Office]
[H.R. 6282 Introduced in House (IH)]
<DOC>
117th CONGRESS
1st Session
H. R. 6282
To amend title III of the Public Health Service Act to eliminate
immunity for manufacturers of COVID-19 vaccines, and for other
purposes.
_______________________________________________________________________
IN THE HOUSE OF REPRESENTATIVES
December 14, 2021
Mr. Perry (for himself and Mr. Gohmert) introduced the following bill;
which was referred to the Committee on Energy and Commerce
_______________________________________________________________________
A BILL
To amend title III of the Public Health Service Act to eliminate
immunity for manufacturers of COVID-19 vaccines, and for other
purposes.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the ``COVID-19 Vaccine Accountability
Act''.
SEC. 2. LIABILITY OF COVID-19 VACCINE MANUFACTURERS.
(a) Covered Countermeasure.--Section 319F-3(i)(1) of the Public
Health Service Act (42 U.S.C. 247d-6d(i)(1)) is amended by adding at
the end the following:
``Such term does not include vaccines for COVID-19 that
are required (directly or as a condition of employment,
schooling, or otherwise) under Federal, State, or local
law to be administered to individuals eligible to
receive such a vaccine.''.
(b) Covered Person.--Section 319F-3(i)(2) of the Public Health
Service Act (42 U.S.C. 247d-6d(i)(2)) is amended by adding at the end
the following:
``Such term does not include a manufacturer of a
vaccine described in the matter following subparagraph
(D) of paragraph (1).''.
(c) Limitation of Liability.--Section 319F-3 of the Public Health
Service Act (42 U.S.C. 247d-6d) is amended by adding at the end the
following:
``(j) Limitation on Liability.--Pursuant to, and consistent with,
the sovereign immunity reservation specified in subsection (f), the
liability of the United States for a death or injury caused by the
administration of a vaccine for COVID-19 occurring on or after January
1, 2020 shall not exceed $10,000.''.
<all>